Detection Rate of 18F-Labeled PSMA PET/CT in Biochemical Recurrent Prostate Cancer: A Systematic Review and a Meta-Analysis
Open Access
- 23 May 2019
- Vol. 11 (5), 710
- https://doi.org/10.3390/cancers11050710
Abstract
Background: The use of radiolabeled prostate-specific membrane antigen positron emission tomography/computed tomography (PSMA PET/CT) for biochemical recurrent prostate cancer (BRPCa) is increasing worldwide. Recently, 18F-labeled PSMA agents have become available. We performed a systematic review and meta-analysis regarding the detection rate (DR) of 18F-labeled PSMA PET/CT in BRPCa to provide evidence-based data in this setting. Methods: A comprehensive literature search of PubMed/MEDLINE, EMBASE, and Cochrane Library databases through 23 April 2019 was performed. Pooled DR was calculated on a per-patient basis, with pooled proportion and 95% confidence interval (95% CI). Furthermore, pooled DR of 18F-PSMA PET/CT using different cut-off values of prostate-specific antigen (PSA) was obtained. Results: Six articles (645 patients) were included in the meta-analysis. The pooled DR of 18F-labeled PSMA PET/CT in BRPCa was 81% (95% CI: 71–88%). The pooled DR was 86% for PSA ≥ 0.5 ng/mL (95% CI: 78–93%) and 49% for PSA < 0.5 ng/mL (95% CI: 23–74%). Statistical heterogeneity was found. Conclusions: 18F-labeled PSMA PET/CT demonstrated a good DR in BRPCa. DR of 18F-labeled PSMA PET/CT is related to PSA values with significant lower DR in patients with PSA < 0.5 ng/mL. Prospective multicentric trials are needed to confirm these findings.Keywords
This publication has 31 references indexed in Scilit:
- Gallium-68 Prostate-specific Membrane Antigen Positron Emission Tomography in Advanced Prostate Cancer-Updated Diagnostic Utility, Sensitivity, Specificity, and Distribution of Prostate-specific Membrane Antigen-avid Lesions: A Systematic Review and Meta-analysisEuropean Urology, 2020
- Imaging of Prostate Specific Membrane Antigen Targeted Radiotracers for the Detection of Prostate Cancer Biochemical Recurrence after Definitive Therapy: A Systematic Review and Meta-AnalysisJournal of Urology, 2019
- Correlation between PSA kinetics and PSMA-PET in prostate cancer restaging: A meta-analysisEuropean Journal of Clinical Investigation, 2019
- Current application and future perspectives of prostate specific membrane antigen PET imaging in prostate cancerPublished by Edizioni Minerva Medica ,2019
- Consensus on molecular imaging and theranostics in prostate cancerThe Lancet Oncology, 2018
- Keeping up with the prostate-specific membrane antigens (PSMAs): an introduction to a new class of positron emission tomography (PET) imaging agentsTranslational Andrology and Urology, 2018
- Advances in prostate cancer imagingF1000Research, 2018
- A Perspective on the Evolving Story of PSMA Biology, PSMA-Based Imaging, and Endoradiotherapeutic StrategiesJournal Of Nuclear Medicine, 2018
- PET/CT With 68Ga-PSMA in Prostate Cancer: Radiopharmaceutical Background and Clinical ImplicationsCurrent Radiopharmaceuticals, 2018
- Prostate-Specific Membrane Antigen Ligands for Imaging and TherapyJournal of Nuclear Medicine, 2017